Future perspectives in pulmonary arterial hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) management is suboptimal despite advances.
• Current treatments focus on three main pathophysiological pathways.
• Complex PAH pathobiology involves additional mechanisms beyond established pathways.

Purpose of the Study:

• To review potential novel therapies for PAH investigated in phase II clinical trials.
• To discuss emerging treatment strategies targeting alternative mechanisms in PAH.
• To identify considerations for developing new PAH therapies.

Main Methods:

• Literature review of phase II clinical trials for PAH therapies.
• Analysis of emerging treatment strategies and techniques.
• Discussion of potential disease mediators and modifiers in PAH.

Main Results:

• Several novel PAH therapies and techniques are under investigation in phase II trials.
• These emerging treatments aim to address mechanisms outside the primary three pathophysiological pathways.
• Considerations for targeting putative disease mediators and modifiers are highlighted.

Conclusions:

• Novel therapeutic approaches are crucial for improving PAH management.
• Phase II trials are evaluating promising new strategies for PAH.
• Further research into disease mediators and modifiers is essential for future treatment development.